PXL770 is a small molecule, direct allosteric AMPK activator (Gluais-Dagorn et al., 2022) currently in Phase 2 development for nonalcoholic steatohepatitis (NASH). This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatohepatitis.